$VRTX

AI Analysis

Generated on May 11, 2026

AI Score
78/ 100
Buy$VRTX

Vertex Pharmaceuticals

$VRTXNASDAQHealthcareLarge-Cap

Vertex discovers and develops medicines for cystic fibrosis and other serious diseases.

Market Cap
$105.0B
Revenue (TTM)
$10.3B
+12.0%
Net Income (TTM)
$3.8B
+15.0%
EPS (TTM)
$14.80
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$350-$500
Beta
0.42
Dimension Scores
Fundamental
80
Technical
72
Sentiment
76
Risk / Reward
78
Momentum
74
FundTechSentRiskMome
Financial Health
Profitability
85strong
Growth
77strong
Liquidity
86strong
Solvency
82strong
Efficiency
78strong

Valuation, technical analysis, investment thesis, risk assessment and more for $VRTX

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.